Navigation Links
Cynosure Files Patent Infringement Lawsuit Against CoolTouch Inc.
Date:1/9/2008

Company and Largest Shareholder El.En. S.p.A. Seek Injunction and Monetary

Damages

WESTFORD, Mass., Jan. 9 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, and its largest shareholder, El.En. S.p.A., today filed a patent infringement lawsuit against CoolTouch Inc. in U.S. District Court for the District of Massachusetts. The lawsuit alleges that CoolTouch's 1320 nm CoolLipo(TM) laser system infringes on U.S. Patent No. 6,206,873 (the 873 patent), which covers technology using laser energy to remove subcutaneous fat. Cynosure is the exclusive licensee of the 873 patent, which is owned by El.En.

The 873 patent is a fundamental component of the Smartlipo(TM) LaserBodyScuplting(SM) Workstation, a groundbreaking system designed as an alternative to traditional liposuction in patients with small areas of localized fat. Cynosure received U.S. Food and Drug Administration clearance to market the Smartlipo workstation in the fourth quarter of 2006. The product, which was launched in early 2007, uses a 1064 nm Nd:YAG laser to deliver energy directly to subcutaneous fat cells, causing them to rupture. The emitted fat-melting energy also coagulates tissue, thus inducing collagen retraction and tissue tightening.

The lawsuit filed by Cynosure and El.En. seeks monetary damages and an injunction against CoolTouch to prohibit further infringement.

"Smartlipo has become the gold standard for the minimally invasive removal of localized fat, and we will vigorously defend our intellectual property position," said Cynosure President and Chief Executive Officer Michael Davin. "As evidenced by the new higher-powered 10- and 18-watt workstations we introduced in 2007, we continue to make significant investments in the future of the Smartlipo workstation. We believe that CoolTouch's device infringes on the 873 patent, and we initiated this litigation to protect our rights and represent the best interest of our shareholders."

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.

For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosure.com.

Safe Harbor

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the company's expectations and future financial performance, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.


'/>"/>
SOURCE Cynosure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cynosure to Present at the Maxim Group Growth Conference
2. Cynosure to Announce Third-Quarter 2007 Financial Results on November 1
3. Alvarado Hospital Files Countersuit Against Blue Shield
4. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
5. Pharsight Files Application for Nasdaq Capital Market Listing
6. Gentiva(R) Health Services Files Universal Shelf Registration Statement
7. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
8. CIGNA Behavioral Health Offers Members Online Provider Profiles
9. American Media Operations, Inc. Files Form 10-Q For First Quarter 2007
10. RxElite Files Registration Statement with Securities and Exchange Commission
11. Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Biotechnology and ... and engagement over the household brands of Top-20 pharma by optimizing clinical trial ... partnering with the right outsourcing payments provider can provide the technology, infrastructure, and ...
(Date:3/27/2017)... ... March 27, 2017 , ... SyncDog, Inc. , the ... partners LG Business Solutions at ATARC Federal Mobile Computing Summit , March ... provide education and examination into the mobility tools and technology employed by the ...
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, the first ... for the Smart System® 20/20. CE Certification builds upon M&S's long-standing commitment to ... such as ANSI, ISO and proven test methods used in the field of ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... can quickly sideline athletes. A type of groin injury, it occurs when the ... to serious, intense pain in and around the lower torso, as well as ...
(Date:3/27/2017)... NY (PRWEB) , ... March 27, 2017 , ... ... in epigenetic research products enables researchers to pursue the recent RNA methylation “gold ... methylation . In light of the newfound characteristics of N6-methyladenosine, or m6A ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... NEW YORK , March 27, 2017 ... ... that adult use in states where cannabis is legal will generate ... $559 million will be from cannabis specific taxes, such as ... remaining $96 million will be earned from state sales taxes that ...
(Date:3/27/2017)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... AGI-134, an immunotherapy for the treatment of multiple cancers, obtained ... featured at the upcoming American Association for Cancer Research ... to be held on April 1-5, 2017. ... An abstract titled ...
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
Breaking Medicine Technology: